Efficacy of surgical treatment of patients with localized gastrointestinal stromal tumors


Cite item

Full Text

Abstract

The main method of the treatment of patients with localized and locally advanced gastrointestinal stromal tumors (GIST) currently remains to be surgical, but its effectiveness is limited and determined by the degree of local expansion of the disease and radicality of the surgery. Before the era of the use of tyrosine kinase inhibitors (TKI) in the treatment of GIST patients the overall 5-year survival after radical surgery in the group of patients with size of the tumor larger than 10 cm failed to exceed 20%. For the time present with the comprehensive approach to the treatment indices of survival in these patients have significantly improved. Overall 5-year survival in patients with a high risk of disease progression reaches 93%. The most important prognostic factors in patients with primary localized GIST are: the size of the primary tumor, mitotic index, tumor location, mutation status and the morphological variant of the cellular structure of GIST.

Keywords

About the authors

Petr P. Arkhiri

N.N. Blokhin Russian Cancer Research Center; Russian Medical Academy of Post-Graduate Education

Email: arhiri@mail.ru
MD, PhD, Doctor of the Surgical Abdominal Oncology Unit of the Thoracoabdominal Department of the Research Institute of Clinical Oncology Moscow, 115478, Russian Federation

I. S Stilidi

N.N. Blokhin Russian Cancer Research Center; Russian Medical Academy of Post-Graduate Education

Moscow, 115478, Russian Federation

I. V Poddubnaya

Russian Medical Academy of Post-Graduate Education

Russian, Moscow, 125993, Russian Federation

S. N Nered

N.N. Blokhin Russian Cancer Research Center; Russian Medical Academy of Post-Graduate Education

Moscow, 115478, Russian Federation

M. P Nikulin

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

V. Yu Bokhyan

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

O. B Abu-Khaydar

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

I. N Peregorodiev

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

S. A Melikov

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

N. Ts Tsymzhitova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

References

  1. Стилиди И.С., Архири П.П., Никулин М.П. Хирургическое лечение больных с первичными локализованными и местнораспространенными гасроинтестинальными стромальными опухолями. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010; 21(1): 77-82.
  2. Стилиди И.С., Архири П.П., Никулин М.П. Роль экономных резекций в плане хирургического лечения больных с локализованными гастроинтестинальными стромальными опухолями (ГИСО). В кн.: Диагностика и лечение онкологических заболеваний пищеварительной системы: материалы Международного конгресса, посвященного 90-летию со дня рождения заслуженного деятеля науки РСФСР и ТАССР, профессора М.З. Сигала. Казань; 2010: 228-9.
  3. Стилиди И.С., Никулин М.П., Сельчук В.Ю., Архири П.П. Оперативное лечение больных с первичными гастроинтестинальными стромальными опухолями. Русский медицинский журнал. 2010; 1(2): 25-9.
  4. Casali P.G., Jost L., Reichardt P., Schlemmer M., Blay J.Y. 2008 ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment anf follow-up. Ann. Oncol. 2008; 19 Suppl. 2: 35-8.
  5. De Matteo R.P, Heinrich M.C, El-Rifai W.M. Clinical management of gastro-intestinal stromal tumors: before end after STI-571. Hum. Pathol. 1999; (30): 1213-20.
  6. De Matteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F.Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231(1): 51-8.
  7. Lasota J., Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin. Diagn. Pathol. 2006; 23 (2): 91-102.
  8. Miettinen M., Lasota J. Gastrointestinal stromal tumors. Review on morphology, molecular pathology, prognosis, and differential siagnosis. Arch. Pathol. Lab. Med. 2006; 130: 1466-76.
  9. Corless C.L., Ballman K.V., Antonescu C., Blanke C.D., Blackstein M.E., Demetri G.D. et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST). Results of the intergroup phase III trial ACOSOG Z9001. J. Clin. Oncol. 2010; 28(15; Suppl.: ASCO Annual Meeting Proceedings (Post-Meeting Edition)): Abstr. 10006.
  10. Анурова О.А., Архири П.П., Мазуренко Н.Н., Мещеряков А.А., Никулин М.П., Носов Д.А. и др. Гастроинтестинальные стромальные опухоли (ГИСО). В кн.: Онкология: Клинические рекомендации / Под ред. М.И. Давыдова. М.: Издательская группа РОНЦ; 2015: 178-83.
  11. Corless C.L., Ballman K.V., Antonescu C.R., Kolesnikova V., Maki R.G., Pisters P.W. et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J. Clin. Oncol. 2014; 32(15): 1563-70.
  12. Joensuu H., Eriksson M., Sundby Hall K., Hartmann J.T., Pink D., Schütte J. et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol. 2011; 29(18, Suppl.: ASCO Annual Meeting Proceedings (Post-Meeting Edition)): Abstr. LBA1.
  13. Arkhiri P., Stilidi I.S., Poddubnaya I., Nered S.N., Bokhian V.Yu., Peregorodiev I.N. et al. The role and optimal duration of adjuvant imatinib therapy in primary GIST patients. J. Clin. Oncol. 2016; 34(15: ASCO Annual Meeting).
  14. Rutkowski P., Gronchi A., Hohenberger P., Bonvalot S., Schöffski P., Bauer S. et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): The EORTC STBSG experience. Ann. Surg. Oncol. 2013; 20: 2937-43.
  15. Demetri G.D., Benjamin R., Blanke C.D., Blay J.Y., Casali P., Choi H. et al. NCCN Task Force report: management of patients with Gastrointestinal Stromal Tumor (GIST) - update of the NCCN clinical practice guidelines. J. Natl. Compr. Conc. Netw. 2007; 5 (Suppl. 2): S1-S29.
  16. Joensuu Heikki. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 2008; 39: 1411-9.
  17. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J. et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum.Pathol. 2002; 33 (5): 459-65.
  18. Aparicio T., Boige V., Sabourin J.C. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur. J. Surg. Oncol. 2004; 30: 1098-103.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies